Eli Lilly 2007 Annual Report Download - page 10

Download and view the complete annual report

Please find page 10 of the 2007 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132


8
Select Drug Candidates in Mid-Stage Investigation
A-beta antibody for Alzheimer’s disease
A-beta lowering for Alzheimer’s disease
(Gamma secretase inhibitor)
Anti-CD20 (AME133v) for non-Hodgkin’s lymphoma (NHL)
ASAP for solid tumors
Factor Xa inhibitor for venous thromboembolism (VTE) prophylaxis, VTE treatment and atrial brillation
stroke prophylaxis
Gemcitabine prodrug for solid tumors
GLP-Fc analog for type 2 diabetes
Glucokinase activator for type 2 diabetes
(in collaboration with OSI Pharmaceuticals, Inc.)
HY10275 for insomnia
IL-1 beta antibody for rheumatoid arthritis
LP10152 (FGF-21) for diabetes
mGlu2/3 prodrug for schizophrenia
NERI IV for depression (phase II); for ADHD (phase I)
OpRA II for alcohol dependence
Survivin ASO for solid tumors
TRPV1 antagonist for treatment for various pain conditions, including osteoarthritic pain
(in collaboration with Glenmark Pharmaceuticals)
Information is current as of January 31, 2008. The search for new drugs is risky and uncertain, and there are no guarantees.
Remaining scientic and regulatory hurdles may cause pipeline compounds to be delayed or even to fail to reach the market.